Cellomics launches Cellomics CellSpace Knowledge Miner
CellSpace is a knowledge mining system that continuously monitors the research literature of molecular and cellular biology, automatically extracting and databasing information regarding relationships between molecules that are at the heart of biomedical research. CellSpace computers continuously analyze the U.S. National Library of Medicine's Medline® database, performing proprietary statistical correlation analyses regarding the organisms, cell types, biological processes and molecules reported on in biomedical research literature.
By using CellSpace, molecular biologists and drug discovery researchers are instantly able to access insights that previously required days or weeks of literature review. With CellSpace, users can determine the biological functions most commonly shared by a cluster of gene products, which is useful for interpreting cDNA microarray data. CellSpace can also determine which protein-protein interactions observed in a two-hybrid screen have not previously been reported in the literature, list all the molecular targets implicated in a disease as well as the drugs known to act upon them, and more. The answer a user receives is much more than a simple annotation retrieved from a curated database; rather, it is a consensus derived from more than one million research publications. All answers are linked back to the reports from which they were derived, enabling the user to judge their accuracy. New research literature is automatically analyzed every two weeks, ensuring that CellSpace is always up-to-date. And, if an update occurs that is relevant to your query, the user can be notified via e-mail immediately.
"The torrent of data now being produced by post-genomic research requires sophisticated new bioinformatics tools to assist us in understanding what all those data mean," stated Dr. William Busa, Cellomics' Chief Scientific Officer and Vice President for Bioinformatics. "Today's CellSpace is the first sophisticated component of what will grow to become a fully automated knowledge representation system, one that enables the automated synthesis of new knowledge from data."
Cellomics is developing and commercializing High Content Screening, informatics, cellular bioinformatics and other products designed to provide customers with in-depth knowledge about cells and cellular functions in order to aid research in drug discovery, basic biomedical research and clinical diagnostics. Currently, Cellomics' ArrayScan® II High Content Screening platforms are in use at multiple sites within ninety (90) percent of the top ten pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies.
For more information: Drew Patrick, Director, Corporate Communications & Investor Relations, Cellomics, Inc., 635 William Pitt Way, Pittsburgh, PA 15238. Tel: 412-826-3600 x 2708. Email: info@cellomics.com.
Visit the Cellomics, Inc. Storefront on Drug Discovery Online.
Source: Cellomics, Inc.
Sign up for our free newsletter.
Send comments to Drug Discovery Online's content manager at contentmanager@drugdiscoveryonline.com.